Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 2012, 08:04 AM   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this
Labels: AEZS, Analysts New Coverage, Market News

Related Stocks

Chart Stock Name Last Change Volume 
  AEZS 1.89 0.00 (0.00%) 126,513 

  Be the first to like this.
 


 

2906  4569  514  590 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 VEON 3.070.00 
 WFT 2.930.00 
 CPN 15.220.00 
 CAA 53.120.00 
 VER 6.810.00 
 FDC 15.670.00 
 HST 19.110.00 
 ECA 10.730.00 
 PPL 29.520.00 
 PE 25.040.00 
Partners & Brokers